Allergan Receives FDA Approval for Migraine Treatment

January 9, 2020

Allergan Receives FDA Approval for Migraine Treatment

UBRELVY™ is the first and only orally-administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the treatment of migraine attacks. The therapy is taken by the user once a migraine starts — UBRELVY then provides relief for up to 24 hours. Yourway supports a patient-centric supply chain so that drugs in clinical trials can reach patients faster, regardless of where they are located.

Back to Index

Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

SCOPE Supply Chain & Logistics Leadership Summit

February 2-5, 2026
Orlando, Florida

Schedule a Meeting

Global Clinical Supplies Group Asia Pacific Conference

March 11-13, 2026
Conrad Seoul Hotel, South Korea

Schedule a Meeting

Media

Articles

Just-in-Time or Plan Ahead? Mastering Logistics Strategies for Complex Clinical Trials

Open chat

Hello! How can I help you?